This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
by Shaun Pruitt
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWest
by Zacks Equity Research
EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWest have been highlighted in this Screen of The Week article.
Ensign Group Expands Healthcare Portfolio With Key Acquisitions
by Zacks Equity Research
ENSG acquires skilled nursing and senior living facilities across four states, expanding its U.S. footprint and bringing higher revenues for its Skilled Services segment.
5 Stocks With Recent Price Strength Defying a Weak February
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are EVER, JAZZ, PGR, SONY, NWG.
Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy?
by Zacks Equity Research
Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stocks to Buy for March 3rd
by Zacks Equity Research
STRL. BATRA and JAZZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 3, 2025.
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like NFG, ENS, TAP and JAZZ are seeing price strength and have a high chance of carrying the momentum forward.
New Strong Buy Stocks for March 3rd
by Zacks Equity Research
Teaser: STRL, CAPL, BATRA, CYD and JAZZ have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2025.
Best Value Stocks to Buy for March 3rd
by Zacks Equity Research
EME, JAZZ and STRL made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 3, 2025.
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
International Markets and Jazz (JAZZ): A Deep Dive for Investors
by Zacks Equity Research
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
by Zacks Equity Research
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 13.99% and 2.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
by Zacks Equity Research
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
by Zacks Equity Research
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
by Zacks Equity Research
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
by Nilanjan Banerjee
JAZZ vs. CTLT: Which Stock Is the Better Value Option?